N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial

Post time 2024-4-26 05:39:33

journal：Progress in Neuro-Psychopharmacology and Biological Psychiatry

Authors：Jerome Sarris; Gerard Byrne; David Castle; Chad Bousman; Georgina Oliver; Lachlan Cribb; Scott Blair-West; Vlasios Brakoulias; David Camfield; Carolyn Ee; Suneel Chamoli; Mark Boschen; Olivia M. Dean; Nathan Dowling; Ranjit Menon; Jenifer Murphy; Najwa-Joelle Metri; Thomas P. Nguyen; Andrew Wong; Rebecca Jordan; Diana Karamacoska; Susan L. Rossell; Michael Berk; Chee H. Ng

Published date：2022-7-

DOI：10.1016/j.pnpbp.2022.110550

PDF link：https://www.sciencedirect.com/sc ... 278584622000422/pdf

Article link：http://dx.doi.org/10.1016/j.pnpbp.2022.110550

Article Source：Elsevier BV。

Remark：

Post time 2024-4-26 05:39:34

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Elsevier] N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial